临床与病理杂志2025，Vol.45Issue(1)：9-17,9.DOI:10.11817/j.issn.2095-6959.2025.241059
联会复合体蛋白2表达水平评估局部晚期宫颈癌患者新辅助化疗效果的应用价值
Application value of synaptonemal complex protein 2 expression in evaluating the efficacy of neoadjuvant chemotherapy in patients with locally advanced cervical cancer
摘要
Abstract
Objective:Synaptonemal complex protein 2(SYCP2)is a testis cancer-associated protein that exhibits abnormal expression in various reproductive tract malignancies and may be associated with chemotherapeutic response in ovarian and breast cancers.However,the relationship between the SYCP2 expression and the efficacy of neoadjuvant chemotherapy(NACT)in patients with locally advanced cervical cancer(LACC)remains unclear.This study aims to investigate the association between the SYCP2 expression and NACT efficacy in LACC patients. Methods:A total of 87 LACC patients treated at the First Affiliated Hospital,the Second Affiliated Hospital,and the Third Affiliated Hospital of Zhengzhou University from June 2021 to June 2024 were enrolled and divided into a high SYCP2 expression group(n=46)and a low SYCP2 expression group(n=41)based on the SYCP2 expression in pathological tissue sections.All patients received 2 cycles of NACT before surgery.The short-term efficacy(objective response rate),changes in serum squamous cell carcinoma antigen(SCCA)levels,quality of life[assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30(EORTC QLQC30)],and incidence of adverse events was compared between the 2 groups. Results:Immunohistochemistry showed negative SYCP2 expression in normal cervical tissues and positive SYCP2 expression in tumor tissues of LACC patients.The objective response rate in the low SYCP2 expression group was 80.49%,significantly higher than 60.87%in the high SYCP2 expression group(P<0.05).Post-treatment,serum SCCA levels significantly decreased in both groups,with lower levels observed in the low SYCP2 expression group compared to the high SYCP2 expression group(P<0.001).Post-treatment EORTC QLQ-C30 scores improved in both groups,and the low SYCP2 expression group had significantly higher scores than the high SYCP2 expression group(P<0.001).The incidence of grade III-IV adverse events was similar between the groups:36.59%(15/41)in the low SYCP2 expression group vs 36.96%(17/46)in the high SYCP2 expression group(χ2=0.001,P=0.971). Conclusion:High SYCP2 expression in LACC patients is associated with lower objective response rate to NACT,higher post-treatment serum SCCA levels,and poorer quality of life compared to the low SYCP2 expression.SYCP2 may serve as a potential molecular biomarker for predicting the efficacy of NACT in LACC patients.关键词
联会复合体蛋白2/局部晚期宫颈癌/新辅助化疗/同步放化疗/鳞状上皮细胞癌抗原/临床疗效Key words
synaptonemal complex protein 2/locally advanced cervical cancer/neoadjuvant chemotherapy/concurrent chemoradiotherapy/squamous cell carcinoma antigen/clinical efficacy引用本文复制引用
侯忠臣,申丹丹,任琛琛,郭鲁伟,林南山,鲁静荷,任芳,徐臻,朱远航,杨立..联会复合体蛋白2表达水平评估局部晚期宫颈癌患者新辅助化疗效果的应用价值[J].临床与病理杂志,2025,45(1):9-17,9.基金项目
河南省科技攻关联合项目(LHGJ20230387) （LHGJ20230387）
河南省科技攻关项目(232102310092) （232102310092）
河南省科创中原项目(2023HYTP048).This work was supported by the Henan Provincial Science and Technology Tackling Joint Project(LHGJ20230387),the Henan Provincial Science and Technology Tackling Project(232102310092),and the Henan Provincial Science and Technology Creation in the Central Plains Project(2023HYTP048),China. （2023HYTP048）
